SERA Stock Analysis: Sera Prognostics Inc Class A
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclam
- Latest close
- $2.02
- 20-day change
- -2.42%
- Trend state
- LEAN BEAR
- Classification
- Healthcare · Medical - Diagnostics & Research
Market context
Sera Prognostics Inc Class A moved -2.42% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
The latest cached company filing period (FY2025 · $81K revenue · -$31.9M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 3.2/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.